Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions

Anti-Cancer Agents in Medicinal Chemistry, 8(1): 86-91.

Author(s): Alssandra Franco.

Affiliation: University of California San Diego, School of Medicine, Department of Pediatrics, Division of Allergy and Immunological Diseases 9500 Gilman Drive La Jolla, CA 92093-0731,USA.


The immune system recognizes and potentially eliminates tumors that express antigenic molecules. The theory of “cancer immunosurveillance”, describing lymphocytes as sentinels capable of recognizing nascent transformed cells and thus maintaining tissue homeostasis, has been proposed as far back as 50 years ago. The modern vision of immune responses against cancer is more complex because the immune system sculpts the immunogenic phenotype of developing tumors by not only facilitating their elimination, but also their progression in regards to the role of regulatory T cells and the subpopulation of natural killer T cells (NKT). Manipulation of adaptive immunity through therapeutic approaches is relevant to prevent metastasis and, in some cases, to treat primary tumors if the relevant antigens have been identified. Here we review the use of glycoconjugates containing tumor-associated carbohydrate antigens (TACA) in immunotherapy and their use as vaccines in clinical and pre-clinical trials. We also describe a new experimental vaccine model for the generation of CD8+ cytotoxic T cells (CTL) that involves designer TACA-containing glycopeptides with high affinity for class I molecules of the major histocompatibility complex (MHC).


Tumor Associated Carbohydrate Antigens, adaptive immunity, cytotoxic T cells.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 1
First Page: 86
Last Page: 91
Page Count: 6
DOI: 10.2174/187152008783330888

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science